Skip to content

The Brief
Reports
The Pulse
- NeuroPulse
- OrphanPulse
Topics

Medicare Advantage Premiums Fall 16.5% for 2027 While Part D Deductibles Rise 30%

Medicare Advantage Premiums Fall 16.5% for 2027 While Part D Deductibles Rise 30%

Athithi Verma September 30, 2026

The premium headline is real, but part of the cost has moved from the monthly bill to the point of care.

Sweden Subsidised Phesgo in Both Early and Metastatic Breast Cancer as Pertuzumab Biosimilars Approach

Sweden Subsidised Phesgo in Both Early and Metastatic Breast Cancer as Pertuzumab Biosimilars Approach

EU Pharma Package Sets Nine Years' Default Protection and Rewards Comparative Trials With a Tenth

EU Pharma Package Sets Nine Years’ Default Protection and Rewards Comparative Trials With a Tenth

Retatrutide Cuts Weight 20.8% in Type 2 Diabetes, and Lilly Plans to File It as a Biologic

Retatrutide Cuts Weight 20.8% in Type 2 Diabetes, and Lilly Plans to File It as a Biologic

Indonesia Is Injecting $1.1 Billion Into BPJS Kesehatan as 52 Million Members Lapse on Premiums

Indonesia Is Injecting $1.1 Billion Into BPJS Kesehatan as 52 Million Members Lapse on Premiums

FDA's Surgical Robot Guidance Prefers Robotic Comparator Data, Which Mostly Means Measuring Challengers Against Intuitive

FDA’s Surgical Robot Guidance Prefers Robotic Comparator Data, Which Mostly Means Measuring Challengers Against Intuitive

Editor’s Pick

Rare Disease Produced Two First-Ever Approvals in Two Days, and Both of Them Are Neurology

Rare Disease Produced Two First-Ever Approvals in Two Days, and Both of Them Are Neurology

In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part

In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part

In Japan, Expanding a Label Is What Triggers the Price Cut

In Japan, Expanding a Label Is What Triggers the Price Cut

NeuroPulse

NeuroPulse Wk 39: Otsuka Opened Early Access the Day Before FUS-ALS Read Out

NeuroPulse Wk 39: Otsuka Opened Early Access the Day Before FUS-ALS Read Out

NeuroPulse Wk 38: Xenon Filed in Epilepsy and Paused in Psychiatry on the Same Day

NeuroPulse Wk 38: Xenon Filed in Epilepsy and Paused in Psychiatry on the Same Day

OrphanPulse

OrphanPulse Wk 39: A 900-Patient Disease Now Has Two Approved Drugs

OrphanPulse Wk 39: A 900-Patient Disease Now Has Two Approved Drugs

OrphanPulse Wk 38: Two Untreatable Childhood Diseases Got First Therapies in 24 Hours

OrphanPulse Wk 38: Two Untreatable Childhood Diseases Got First Therapies in 24 Hours

DealPulse Signal

DealPulse Signal Wk 39: Telix Paid in Stock and the Platforms Paid in Promises

DealPulse Signal Wk 39: Telix Paid in Stock and the Platforms Paid in Promises

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Report

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

The Beats

DealPulse Signal Wk 39: Telix Paid in Stock and the Platforms Paid in Promises

DealPulse Signal Wk 39: Telix Paid in Stock and the Platforms Paid in Promises

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

Analysis

Radiopharmaceuticals: sixteen years of deal data on where the field goes next

Radiopharmaceuticals: sixteen years of deal data on where the field goes next

Behind the Headlines How the Leaders Really Performed

Behind the Headlines: How the Leaders Really Performed

Reshaping Pharma by 2027

7 Market Access Trends Reshaping Pharma by 2027

Coverage

ADCs Returned 0.46 in Relapsed Disease and 1.15 in the Front Line at WCLC

The ADC Decade Accelerates What to Watch at ASCO 2026

The ADC Decade Accelerates: What to Watch at ASCO 2026

The Briefs

Medicare Advantage Premiums Fall 16.5% for 2027 While Part D Deductibles Rise 30%

Medicare Advantage Premiums Fall 16.5% for 2027 While Part D Deductibles Rise 30%

Athithi Verma September 30, 2026

Sweden Subsidised Phesgo in Both Early and Metastatic Breast Cancer as Pertuzumab Biosimilars Approach

Sweden Subsidised Phesgo in Both Early and Metastatic Breast Cancer as Pertuzumab Biosimilars Approach

Athithi Verma September 30, 2026

EU Pharma Package Sets Nine Years' Default Protection and Rewards Comparative Trials With a Tenth

EU Pharma Package Sets Nine Years’ Default Protection and Rewards Comparative Trials With a Tenth

Athithi Verma September 30, 2026

Retatrutide Cuts Weight 20.8% in Type 2 Diabetes, and Lilly Plans to File It as a Biologic

Retatrutide Cuts Weight 20.8% in Type 2 Diabetes, and Lilly Plans to File It as a Biologic

Athithi Verma September 30, 2026

Indonesia Is Injecting $1.1 Billion Into BPJS Kesehatan as 52 Million Members Lapse on Premiums

Indonesia Is Injecting $1.1 Billion Into BPJS Kesehatan as 52 Million Members Lapse on Premiums

Athithi Verma September 30, 2026

FDA's Surgical Robot Guidance Prefers Robotic Comparator Data, Which Mostly Means Measuring Challengers Against Intuitive

FDA’s Surgical Robot Guidance Prefers Robotic Comparator Data, Which Mostly Means Measuring Challengers Against Intuitive

Athithi Verma September 29, 2026

Explore Synopulse

NeuroPulse
Deals
Market Access
Industry Trends
Regulatory

About

About Synopulse
Contact Us
Announcements

© 2026 Synopulse • Built with GeneratePress